PBAC DUSC utilisation refresh creates a stronger evidence feedback loop for reimbursement resubmissions.
PBS updates published on 20 March 2026 refreshed DUSC utilisation analysis access, creating a practical trigger for market access teams to re-baseline assumptions, tighten evidence traceability, and align comparative evidence with budget-impact and cost-effectiveness updates.
IQWiG dossier assessment A25-154, published 16 March 2026, reassesses adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma and reports a sex-specific benefit pattern based on direct randomized evidence from CheckMate 274.
PBAC's equitable-access GLP-1 framework: a managed-rollout playbook for obesity market access
On 16 March 2026, IQWiG completed project A25-153 for lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma and reported added benefit not proven, citing absence of direct comparator-aligned evidence and methodological limitations of unanchored MAIC analyses built from single-arm sources.
NCPE’s perioperative pembrolizumab position shows the bottleneck: cost-effectiveness under uncertainty when indirect evidence informs decisions.
On 10 March 2026, the National Centre for Pharmacoeconomics recommended perioperative pembrolizumab in resectable high-risk NSCLC be considered for reimbursement if cost-effectiveness improves, citing strong direct trial evidence versus chemotherapy and uncertain indirect comparative estimates versus nivolumab-based care.
MHRA’s Onkotrone Class 4 notice is a labeling-governance signal, not a new effectiveness finding—still critical for evidence communication.
The Medicines and Healthcare products Regulatory Agency published Class 4 Medicines Defect Notification EL(26)A/14 on 17 March 2026 for Onkotrone batches where the included patient leaflet did not reflect updated contraception-duration wording. The agency basis is a labelling-information defect, not a new comparative effectiveness assessment.
The 19 March 2026 G-BA resolution on mirdametinib in symptomatic, inoperable NF1 plexiform neurofibromas found a non-quantifiable added benefit at hint-level certainty. Decision text shows how Germany may acknowledge meaningful single-arm efficacy while withholding magnitude quantification when control-based comparative interpretation is structurally constrained.
FDA approved ICOTYDE for moderate-to-severe plaque psoriasis in adults and eligible adolescents on 17 March 2026. Label evidence from PSO-1 through PSO-4 shows robust placebo separation and active-comparator advantages versus deucravacitinib in key co-primary endpoints, creating a strong base for subsequent HTA comparative work.
EMA CHMP issued a positive opinion for Onerji on 26 February 2026 in advanced Parkinson disease with uncontrolled motor fluctuations on oral therapy. Public primary documents confirm decision status, indication scope, and high-level benefit rationale, while trial-level comparative detail remains limited before European Commission decision and full SmPC release.
A rapid March 2026 rise in newly indexed network meta-analyses across fatigue, bipolar depression, and rheumatoid arthritis highlights an execution gap for evidence teams: turning fast-moving comparative evidence into dossier-grade outputs requires explicit endpoint, comparator, and time-window governance.
AbangeLabs